Abstract
Molecular targeting therapy is becoming the standard of care for some patients with anaplastic lymphoma kinase (ALK)-rearranged lung adenocarcinoma. Drug-related pneumonitis (DRP) has been identified as an infrequent but potentially severe adverse effect. Herein, we report a 50-year-old woman with ALK-rearranged advanced lung adenocarcinoma who developed interstitial lung disease associated with alectinib therapy. At 102-day of treatment, chest CT revealed scattered ground glass opacities (GGOs) involving both lungs. Since she was asymptomatic and alectinib provided a beneficial tumor treatment response, alectinib therapy was continued. However, 2 months later, she presented with progressive dyspnea and diffuse GGOs on chest computed tomography. There was no evidence for infection or other etiologies for her lung complication. Alectinib was discontinued and steroid therapy was initiated which was followed by improvement in respiratory symptoms and chest CT findings; DRP was diagnosed. Although rare, alectinib therapy can cause DRP of indolent onset.
Introduction
With an estimated 2.2 million new cases and 1.8 million deaths, lung cancer is the second most commonly diagnosed cancer and the leading cause of cancer death globally in 2020 (Sung et al., 2021), of which non-small cell lung cancer (NSCLC) accounts for about 85% (Herbst et al., 2018). As a driver mutation, anaplastic lymphoma kinase (ALK)-rearrangement accounts for 2%–7% of all cases of NSCLC (Golding et al., 2018). Alectinib, a second-generation ALK inhibitor, was recommended by the National Comprehensive Cancer Network (NCCN) as first-line therapy for patients with ALK-positive NSCLC (Ettinger et al., 2018). However, drug-related pneumonitis (DRP) caused by use of ALK inhibitors has been identified as an infrequent but potentially severe adverse effect. Several cases of DRP have been reported with the first-generation ALK inhibitor, crizotinib [(Wu et al., 2018); (Yoneda et al., 2017)]. Herein, we report a case of interstitial lung disease (ILD) of indolent onset in a patient with ALK rearrangement NSCLC receiving alectinib therapy, a second-generation ALK inhibitor.
Case presentation
A 50-year-old female farmer, presented to the department of Rheumatology in our hospital for swelling of both lower extremities and pain in both knees and ankles for half a year. She had no relevant past medical history and was a lifelong nonsmoker with no history of alcohol intake. She denied any history of relevant environmental or occupational exposures. Autoimmune serologic screening for connective tissue diseases yielded negative results. Chest computed tomography (CT) revealed a lung mass in the left lower lobe (Figure 1A). Subsequently, CT-guided biopsy showed ALK rearrangement, lung adenocarcinoma. Metastases were found in bone and brain. She was diagnosed with stage IV (cT2N0M1c) ALK-rearranged NSCLC. Since the autoimmune serologic screening for connective tissue diseases yielded negative results, and the patient had bone metastases from lung adenocarcinoma, it was considered that the swelling of both lower extremities and pain in knees and ankles were related to pulmonary hypertrophic osteoarthropathy secondary to lung cancer. Therefore, she was started on first-line alectinib therapy at 600 mg twice daily.
FIGURE 1
One month after alectinib administration, chest CT showed tumor shrinkage (Figure 1B) and the swelling of both lower extremities and pain in both knees and ankles were significantly reduced. However, 102 days after initiation of alectinib therapy, chest CT revealed new scattered ground glass opacities (GGOs) involving both lungs (Figure 1C). Alectinib-related ILD Grade 1 (Common Terminology Criteria for Adverse Events version 5.0) was suspected (Cancer Therapy Evaluation Program, 2017). Since she was asymptomatic and alectinib provided a significant therapeutic response, we chose to continue alectinib therapy with careful monitoring.
On the 185th day of alectinib treatment, she was admitted to our department with progressive dyspnea and chest CT showed diffuse GGOs in both lungs (Figure 1D). On physical examination, the patient’s temperature was 36.8°C, pulse 103 beats per minute, respiratory rate 20 beats per minute, blood pressure 128/92mmHg, and oxygen saturation 92% on ambient air. The lungs were clear to auscultation, and inspiratory fine crackles were audible in both lower lungs. Cardiac examination revealed tachycardia, regular rhythm. Abdomen was soft and nontender. There was no lower extremity edema. An arterial blood gas analysis on supplemental oxygen via nasal cannula at flow rate of 2 l/min revealed a PaO2 of 78 mmHg, a PaCO2 of 43.6 mmHg, and a pH of 7.432. Laboratory findings including serum levels of C-reactive protein (<0.5 mg/l), procalcitonin (<0.10 ng/ml), white blood cell count (4.95 x103/ml), neutrophil percentage (67.8%), and eosinophil percentage (5.4%) were within the normal range. Other laboratory findings, including indicators of hepatic and renal function, and autoantibodies were unremarkable. Furthermore, cardiac workup including brain natriuretic peptide level and echocardiography was normal. An extensive search for pathogens, including respiratory viruses, bacteria, and fungi, was negative on the bronchoalveolar lavage fluid (BAL) using metagenomics next-generation sequencing method. After being diagnosed with NSCLC, she had never taken any medications or supplements except for oral alectinib. Based on these results, alectinib-related ILD Grade 3 (Common Terminology Criteria for Adverse Events version 5.0) was suspected (Cancer Therapy Evaluation Program, 2017).
Alectinib was discontinued, and intravenous methylprednisolone (40 mg/day) treatment was instituted. One week later, her dyspnea was resolved with no need for supplemental oxygen. Chest CT revealed near-complete resolution of GGOs (Figure 1E). The patient was discharged at 15 days after admission. Oral prednisolone was administered at 20 mg/day, tapered, and stopped after 2 weeks. Four weeks after discontinuation of alectinib, the MRI of the brain showed new lesions in the bilateral parietal lobe and left occipital lobe. The patient declined treatment with another ALK inhibitors such as lorlatinib due to concerns over potential adverse effects and family’s financial difficulties. Therefore, following a careful discussion of the potential risks and alternatives, she started on second-line therapy with lobaplatin 50mg/m2 plus pemetrexed 500 mg/m2. At the recent follow-up (2 months later), she had no symptoms of dyspnea with no recurrence of ILD in chest CT (Figure 1F). The swelling of both lower extremities and pain in both knees and ankles were completely resolved.
Discussion and conclusions
To our knowledge, this is the first reported case of alectinib-related ILD that manifested an indolent onset and gradual progression during continued alectinib therapy but completely resolved after discontinuation of alectinib. In most other reports, alectinib was discontinued immediately after the occurrence of ILD, and the ILD improved sequentially (Table 1) (Ikeda et al., 2015; Yamamoto et al., 2015; Nitawaki et al., 2017; Gadotti et al., 2021; Huang et al., 2021; Myall et al., 2021; Zhu et al., 2021). Two patients were reported to have continued alectinib treatment after developing asymptomatic ILD without exacerbation of ILD ((Nitawaki et al., 2017); (Hwang et al., 2019)). In our report, although this patient manifested increasing pulmonary infiltrates during 2 months of continued alectinib therapy after initial detection of possible DRP, complete resolution of DRP occurred with cessation of alectinib and glucocorticoid therapy.
TABLE 1
| Case No | Race/year | Demographics | Time to Onset of ILD* | Symptoms | Lung Abnormalities on HRCT | Treatments and Outcomes of ILD | Sequential Treatments and Outcomes of Lung Cancer |
|---|---|---|---|---|---|---|---|
| 1 (Yamamoto et al., 2015) | Japanese/2015 | 86years/Female | 215 days | Dyspnea, pyrexia | GGO, consolidations | Discontinue alectinib and corticosteroid. Improved | NA |
| 2 (Ikeda et al., 2015) | Japanese/2015 | 75years/Female | 102 days | NA | GGO, patchy | Discontinue alectinib. Improved | NA |
| 3 (Nitawaki et al., 2017) | Japanese/2017 | 57years/Male | 33 days | NA | GGO | Discontinue alectinib. Improved | Alectinib. NA |
| 4 (Nitawaki et al., 2017) | Japanese/2017 | 64years/Female | 12 months | Cough | GGO | Continue alectinib. Improved | Alectinib. NA |
| 5 (Myall et al., 2021) | Asian/2018 | 80years/Male | 18 days | Dyspnea, chest pain | GGO | Discontinue alectinib and corticosteroid. Improved | Lorlatinib. Died 7 months after tumor diagnosis |
| 6 (Myall et al., 2021) | Caucasian/2018 | 66years/Female | 26 days | Dyspnea | GGO | Discontinue alectinib and corticosteroid. Improved | Lorlatinib. Partial response of tumor for >10 months |
| 7 (Hwang et al., 2019) | American/2018 | 46years/Female | 28 days | Dyspnea, cough | Septal thickening and bilateral “crazy paving” pattern | Continue alectinib and corticosteroid. Improved | Alectinib. NA |
| 8 (Gadotti et al., 2021) | Brazilian/2018 | 54years/Male | 32 days | Dyspnea | Diffuse reticular interstitial opacities | Discontinue alectinib, corticosteroid and mechanical ventilation. Improved | Alectinib. NA |
| 9 (Huang et al., 2021) | Chinese/2020 | 76years/Female | 31 days | Dyspnea | GGO, patchy | Discontinue alectinib, corticosteroid and mechanical ventilation. Improved | Alectinib. Stable disease of tumor for 16 months |
| 10 (Zhu et al., 2021) | Chinese/2021 | 65years/Male | 27 days | Dyspnea | GGO | Discontinue alectinib and corticosteroid. Improved | Crizotinib. Stable disease of tumor for 6 months |
Literature review of alectinib-related interstitial lung disease.
*Time to onset is defined as the duration in days or months from initiation of alectinib therapy to presentation with interstitial lung disease; ILD, interstitial lung disease; GGO, ground glass opacity; NA, not available.
Alectinib, a second-generation ALK inhibitor, is a key drug for treating patients with ALK-positive NSCLC. A pooled analysis showed that alectinib had good efficacy against brain metastases in ALK-positive NSCLC, because it demonstrated a high brain-to-plasma ratio and was transported independently of the efflux transporter, P-glycoprotein (Gadgeel et al., 2016). Therefore, our patient was treated with alectinib as the first-line treatment due to the presence of ALK-positive and brain/bone metastases.
Use of molecular-targeting agents has increased the frequency and broadened the spectrum of lung toxicity, particularly in patients with cancer. Lung toxicity has been reported in patients taking ALK inhibitors such as crizotinib, ceritinib, lorlatinib and alectinib, with incidence rates of 1.8%, 1.1%, 1.8% and 2.6%, respectively (Pellegrino et al., 2018). DRP (interstitial lung disease) is the most common lung toxicity. The symptoms of DRP are nonspecific and some patients may be asymptomatic even in the presence of diffuse pulmonary opacities. DRP can manifest various histologic patterns and, accordingly, diverse chest CT findings. Some of the commonly encountered patterns include interstitial pneumonia either as acute interstitial pneumonia (diffuse alveolar damage) or transient lung abnormality (simple pulmonary eosinophilia), subacute interstitial disease (organizing pneumonia and hypersensitivity pneumonitis), and chronic interstitial disease (nonspecific interstitial pneumonia) (Johkoh et al., 2021). It is difficult to differentiate pulmonary infiltrates related to DRP from other causes such as infections, pulmonary hemorrhage, pulmonary edema, radiation-induced pneumonitis, and metastases. In general, DRP is suspected when the following criteria are met: 1) exposure to the causative drug; 2) development of pulmonary infiltrates; 3) meticulous exclusion of all other possible causes; 4) cessation of exposure resulting in measurable improvement of symptoms and imaging abnormalities; and 5) rechallenge (often not advisable) causing worsening (Skeoch et al., 2018). Our patient meted criteria 1 to 4, and Yamamoto et al, (2015) reported a patient with alectinib-induced ILD who had GGO and the symptom of progressive dyspnea, similar to our patient.
Currently, the precise mechanisms and risk factors associated with alectinib-related ILD are not fully understood. Some risk factors for DRP associated with other molecularly targeted drugs have been identified. Gemma et al. showed that concurrent/previous ILD, emphysema or chronic obstructive pulmonary disease, lung infection, smoking history, and shorter interval from initial cancer diagnosis to the start of treatment (<360 days) to be significant risk factors for developing ILD in patients receiving erlotinib therapy (Gemma et al., 2014). A study from Japan demonstrated that age 55 years or older, Eastern Cooperative Oncology Group performance status 2-4, smoking history, previous or concomitant ILD, and comorbid pleural effusion to be statistically significant risk factors for crizotinib-related pneumonitis (Gemma et al., 2019). Whether molecular targeting drugs-related DRP has a similar pathophysiology remains to be explored.
At present, the optimal management of alectinib-related ILD remains unclear. The drug labeling of alectinib recommends immediate discontinuation of the drug in cases of suspected DRP, and permanent discontinuation of the drug if no other underlying causes of ILD or non-infectious pneumonia are identified. However, in previous reports, patients did not redevelop DRP after restarting or reducing the dose of alectinib ((Nitawaki et al., 2017); (Gadotti et al., 2021); (Huang et al., 2021); (Hwang et al., 2019)). Furthermore, there were several case reports describing the successful use of crizotinib or lorlatinib in patients with ALK-rearranged NSCLC who have recovered from DRP secondary to alectinib therapy [(Myall et al., 2021); (Zhu et al., 2021)]. Therefore, further studies will be required to determine whether changing to another ALK inhibitors, restarting alectinib, or using alectinib combined with glucocorticoid therapy may be an option after the symptoms of alectinib-related ILD subside.
Both pulmonologists and oncologists should be aware of the possibility of DRP in patients receiving alectinib. Once alectinib-related pneumonitis is suspected, discontinuation of the drug and steroid treatments should be considered.
Statements
Data availability statement
The original contributions presented in the study are included in the article/supplementary materials, further inquiries can be directed to the corresponding author.
Ethics statement
Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.
Author contributions
XH and LC conceived the idea, designed, and supervised the study. XC drafted the manuscript. XC and DX had full access to all the data and took responsibility for the integrity of the data. XJ and JR modified the manuscript. All the authors reviewed and approved the final version of the manuscript.
Funding
Key medical and health specialty construction project of Anhui Province (2021szdzk05).
Acknowledgments
We acknowledged the patient who consented to donate her data for analysis and all health-care workers involved in the diagnosis and treatment of patients in the First Affiliation Hospital of University of Science and Technology (Anhui Provincial Hospital) for their commitment to patient care.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
Cancer Therapy Evaluation Program (2017). Common terminology criteria for adverse events. version 5.0 Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf (Accessed May 1, 2022).
2
EttingerD. S.AisnerD. L.WoodD. E.AkerleyW.BaumanetJ.ChangJ. Y.et al (2018). NCCN guidelines insights: Non-small cell lung cancer, version 5.2018. J. Natl. Compr. Canc. Netw.16, 807–821. 10.6004/jnccn.2018.0062
3
GadgeelS. M.ShawA. T.GovindanR.GandhiL.SocinskiM. A.CamidgeD. R.et al (2016). Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive non-small-cell lung cancer. J. Clin. Oncol.34, 4079–4085. 10.1200/JCO.2016.68.4639
4
GadottiL. L.CanedoF. S. N. A.RibeiroM. F. S. A.SacardoK. P.SaddiR.Machado AlessiJ. V.et al (2021). Successful drug rechallenge following severe acute alectinib-induced interstitial lung disease in a patient with advanced ALK-rearranged lung adenocarcinoma. Clin. Lung Cancer22, e481–e486. 10.1016/j.cllc.2020.06.021
5
GemmaA.KudohS.AndoM.OheY.NakagawaK.JohkohT.et al (2014). Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10, 708 Japanese patients with non-small-cell lung cancer. Cancer Sci.105, 1584–1590. 10.1111/cas.12550
6
GemmaA.KusumotoM.KuriharaY.MasudaN.BannoS.EndoY.et al (2019). Interstitial lung disease onset and its risk factors in Japanese patients with ALK-positive NSCLC after treatment with crizotinib. J. Thorac. Oncol.14, 672–682. 10.1016/j.jtho.2018.11.022
7
GoldingB.LuuA.JonesR.Viloria-PetitA. M. (2018). The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC). Mol. Cancer17, 52. 10.1186/s12943-018-0810-4
8
HerbstR. S.MorgenszternD.BoshoffC. (2018). The biology and management of non - small cell lung cancer. Nature553, 446–454. 10.1038/nature25183
9
HuangJ. R.ChouC. W.ChaoH. S. (2021). Successful rechallenge of alectinib after remission of severe alectinib-induced interstitial lung disease. J. Oncol. Pharm. Pract.27, 1311–1314. 10.1177/1078155220961557
10
HwangA.IskandarA.DasanuC. A. (2019). Successful re-introduction of alectinib after inducing interstitial lung disease in a patient with lung cancer. J. Oncol. Pharm. Pract.25, 1531–1533. 10.1177/1078155218820580
11
IkedaS.YoshiokaH.AritaM.SakaiT.SoneN.NishiyamaA.et al (2015). Interstitial lung disease induced by alectinib (CH5424802/RO5424802). Jpn. J. Clin. Oncol.45, 221–224. 10.1093/jjco/hyu183
12
JohkohT.LeeK. S.NishinoM.TravisW. D.RyuJ. H.LeeH. Y.et al (2021). Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: A position paper from the fleischner society. Chest159, 1107–1125. 10.1016/j.chest.2020.11.027
13
MyallN. J.LeiA. Q.WakeleeH. A. (2021). Safety of lorlatinib following alectinib-induced pneumonitis in two patients with ALK-rearranged non-small cell lung cancer: A case series. Transl. Lung Cancer Res.10, 487–495. 10.21037/tlcr-20-564
14
NitawakiT.SakataY.KawamuraK.IchikadoK. (2017). Case report: Continued treatment with alectinib is possible for patients with lung adenocarcinoma with drug-induced interstitial lung disease. BMC Pulm. Med.17, 173. 10.1186/s12890-017-0519-y
15
PellegrinoB.FacchinettiF.BordiP.SilvaM.GnettiL.TiseoM. (2018). Lung toxicity in non-small-cell lung cancer patients exposed to ALK inhibitors: Report of a peculiar case and systematic review of the literature. Clin. Lung Cancer19, e151–e161. 10.1016/j.cllc.2017.10.008
16
SkeochS.WeatherleyN.SwiftA. J.OldroydA.JohnsC.HaytonC.et al (2018). Drug-induced interstitial lung disease: A systematic review. J. Clin. Med.7, 356. 10.3390/jcm7100356
17
SungH.FerlayJ.SiegelR. L.LaversanneM.SoerjomataramI.JemalA.et al (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca. Cancer J. Clin.71, 209–249. 10.3322/caac.21660
18
WuS.LiuK.FengR.ZhengD.DengP. (2018). Fatal interstitial lung disease associated with crizotinib pathologically confirmed by percutaneous lung biopsy in a patient with ROS1-rearranged advanced non-small-cell lung cancer: A case report. BMC Pulm. Med.18, 121. 10.1186/s12890-018-0682-9
19
YamamotoY.OkamotoI.OtsuboK.IwamaE.HamadaN.HaradaT.et al (2015). Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement–positive non–small cell lung cancer treated with alectinib. Invest. New Drugs33, 1148–1150. 10.1007/s10637-015-0284-9
20
YonedaK. Y.ScrantonJ. R.CadoganM. A.TassellV.NadanacivaS.WilnerK. D.et al (2017). Interstitial lung disease associated with crizotinib in patients with advanced non-small cell lung cancer: Independent review of four PROFILE trials. Clin. Lung Cancer18, 472–479. 10.1016/j.cllc.2017.03.004
21
ZhuN.LinS.HeL.WangL.KongW.CaoC. (2021). Successful treatment with crizotinib after alectinib-induced interstitial lung disease. SAGE Open Med. Case Rep.9, 2050313X211042991–4. 10.1177/2050313X211042991
Summary
Keywords
alectinib, anaplastic lymphoma kinase, lung cancer, drug-related pneumonitis, interstitial lung disease
Citation
Chen X, Xia D, Jiang X, Cao L, Ryu JH and Hu X (2022) Case report: Indolent drug-related pneumonitis with alectinib therapy in the treatment of non-small cell lung cancer. Front. Pharmacol. 13:944685. doi: 10.3389/fphar.2022.944685
Received
15 May 2022
Accepted
20 October 2022
Published
01 November 2022
Volume
13 - 2022
Edited by
Nehad M. Ayoub, Jordan University of Science and Technology, Jordan
Reviewed by
Xin Sun, Zhejiang University, China
Tetsuhiko Asao, Juntendo University, Japan
Chao Cao, Ningbo First Hospital, China
Updates
Copyright
© 2022 Chen, Xia, Jiang, Cao, Ryu and Hu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xiaowen Hu, hu.xiaowen@hotmail.com
This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.